Edgewise Therapeutics (EWTX)
US Market

Edgewise Therapeutics (EWTX) Stock Price & Analysis


EWTX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$5.12 - $11.48
Previous Close$6.5
Average Volume (3M)261.66K
Market Cap
Enterprise Value$128.33M
Total Cash (Recent Filing)$289.70M
Total Debt (Recent Filing)$5.53M
Price to Earnings (P/E)-4.6
Feb 22, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding63,461,608
10 Day Avg. Volume581,174
30 Day Avg. Volume261,662
Standard Deviation0.15
Financial Highlights & Ratios
Price to Book (P/B)1.42
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.66
Price Target Upside306.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5



Ownership Overview

17.79% Mutual Funds
81.35% Other Institutional Investors
0.86% Public Companies and
Individual Investors


What was Edgewise Therapeutics’s price range in the past 12 months?
Edgewise Therapeutics lowest stock price was $5.12 and its highest was $11.48 in the past 12 months.
    What is Edgewise Therapeutics’s market cap?
    Currently, no data Available
    When is Edgewise Therapeutics’s upcoming earnings report date?
    Edgewise Therapeutics’s upcoming earnings report date is Feb 22, 2024 which is in 77 days.
      How were Edgewise Therapeutics’s earnings last quarter?
      Edgewise Therapeutics released its earnings results on Nov 09, 2023. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.396 by -$0.014.
        Is Edgewise Therapeutics overvalued?
        According to Wall Street analysts Edgewise Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Edgewise Therapeutics pay dividends?
          Edgewise Therapeutics does not currently pay dividends.
          What is Edgewise Therapeutics’s EPS estimate?
          Edgewise Therapeutics’s EPS estimate is -$0.45.
            How many shares outstanding does Edgewise Therapeutics have?
            Edgewise Therapeutics has 63,461,610 shares outstanding.
              What happened to Edgewise Therapeutics’s price movement after its last earnings report?
              Edgewise Therapeutics reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.396. Following the earnings report the stock price went down -7.293%.
                Which hedge fund is a major shareholder of Edgewise Therapeutics?
                Among the largest hedge funds holding Edgewise Therapeutics’s share is Viking Global Investors LP. It holds Edgewise Therapeutics’s shares valued at 35M.


                  Company Description

                  Edgewise Therapeutics

                  Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.


                  Top 5 ETFs holding EWTX

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Fidelity Disruptive Medicine ETF
                  Schwab U.S. Broad Market ETF
                  iShares Russell 3000 ETF
                  Vanguard Russell 3000 ETF
                  Up to five ETFs with an Outperform Smart Score that hold EWTX. The ETFs are listed according to market value of EWTX within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Arbutus Biopharma
                  Mirati Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis